Robert Johnson

So in this study, it's showing the integration period.

And psychedelics, I think, it's almost become like it's been used so much it's kind of lost its meaning.

But that's where you take psychedelics and then it's not just the seeing colors or really enjoying that psychedelic jazz music, but it's what you take away from it

after the experience, after you come down that night, and then days or weeks afterwards.

And so that period, they're studying brains on different psychedelics and afterwards.

So for example, ketamine, which gets lumped into the category of psychedelics, even though it's more of a dissociate, it does have some of these brain neurogenesis, neuroplasticity effects.

Now the effects only last like three days afterwards where your brain is more receptive to this change.

And also too, it's more receptive if you were to have some sort of traumatic experience in that.

period right after you took it as well, right?

You're a lot more sensitive.

Now, on the other hand, like LSD, it doesn't have a three-day period.

It has a 30-day period where your brain is more receptive to this kind of being able to form new paths.

So I find that just similar to cannabis, right?

Like as a cannabis user, as a psychedelic user for most of my life, it's awesome now to see scientists basically taking anecdotes of drug users, you know,

are the plant medicine users and using that as like hypothesis for their studies and then showing how, you know, proving neurologically what people have been smoking weed or taking mushrooms, you know, for the past hundred years have been telling them all along.

Well, optimistic?

It's hard to be optimistic about much of these days.

I think on a long enough timeline, it's inevitable.

And it's following the same path as cannabis.

We almost had MDMA approved by the FDA last year for psychedelic-assisted therapy.